Objective:Flebogrif® is a new mechanochemical ablation (MOCA) technique for treating chronic venous disorders (CVD), with limited studies available. This study provides early clinical outcomes from its use in South Korea.

Methods:A retrospective analysis was conducted on 55 patients treated with Flebogrif®at a Charm Vascular Clinic in Seoul. Mechanical injury combined with foam sclerosant (2% STS and CO 2 ) was applied to 113 saphenous veins. Primary outcomes were anatomical success at 1 and 3 months, with secondary outcomes included adverse events, pain scores, rVCSS score, CIVIQ14 score, time to return to normal activities and foam sclerosant dosages.

Results:The anatomical success rate were analyzed as 97.3% at 1 month and 96.9% at 3 months. Adverse events were mild, with no occurrences of severe events such as paresthesia or deep vein thrombosis (DVT). The mean time returned to normal activities was 1.07±0.42 days. Notably, Flebogrif® allowed treatment of multiple veins without increased risk, averaging a foam sclerosant volume of 15.85±5.71 cc per procedure. rVCSS and CIVIQ14 scores showed a statistically significant decrease from the initial scores.

Conclusion:Flebogrif® shows promise as an effective and safe treatment for CVD, achieving comparable results to other methods with potential cost benefits. Further studies are recommended for validation.